EU, China approve Sarclisa + standard of care for MM

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

FDA approved an oral combination of Inqovi (decitabine and cedazuridine) plus venetoclax as a treatment for adults with newly diagnosed acute myeloid leukemia who are 75 years or older or who are ineligible for intensive induction chemotherapy.

May 15, 2026

Vol.52 No.19

Drugs & Targets

Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program

FDA approved Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma.

May 15, 2026

Vol.52 No.19

Drugs & Targets

FDA approves Jakafi XR tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease

FDA has approved Jakafi XR (ruxolitinib) extended-release tablets for the treatment of adults with intermediateor high-risk myelofibrosis; adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease or chronic GVHD after failure of one or two lines of systemic therapy.

May 08, 2026

Vol.52 No.18

In Brief

Murad Mamedov joins Wistar Institute Center for Advanced Therapeutics

Murad Mamedov was named assistant professor in Wistar’s Center for Advanced Therapeutics at the Wistar Institute.

April 03, 2026

Vol.52 No.13

Drugs & Targets

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation based on results from the global phase III BREAKWATER trial.

February 27, 2026

Vol.52 No.08

Drugs & Targets

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

FDA approved Hernexeos (zongertinib tablets) for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.

February 27, 2026

Vol.52 No.08

EU, China approve Sarclisa + standard of care for MM

YOU MAY BE INTERESTED IN

FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML

Bizengri gets FDA approval for bile cancer, becomes seventh drug approved under the priority voucher program

FDA approves Jakafi XR tablets for myelofibrosis, polycythemia vera, and graft-versus-host disease

Murad Mamedov joins Wistar Institute Center for Advanced Therapeutics

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login